Neurizon Therapeutics (ASX:NUZ) Cash Flow from Operations : A$-5.17 Mil (TTM As of Dec. 2023)

Neurizon Therapeutics Cash Flow from Operations Chart

Neurizon Therapeutics Annual Data
	Trend	Jun15	Jun16	Jun17	Jun18	Jun19	Jun20	Jun21	Jun22	Jun23	Jun24
Cash Flow from Operations		Get a 7-Day Free Trial					-1.27	-0.94	-1.33	-1.56	-5.17

Neurizon Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash Flow from Operations	Get a 7-Day Free Trial															-0.40	-0.08	-1.49	-0.05	-5.12

Neurizon Therapeutics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Neurizon Therapeutics's Cash Flow from Operations for the fiscal year that ended in Jun. 2023 is calculated as:

Neurizon Therapeutics's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:

Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-5.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurizon Therapeutics  (ASX:NUZ) Cash Flow from Operations Explanation

For non-financial companies reported in direct method, cash flow from operations contains eight items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

Neurizon Therapeutics's cash receipts from operating activities for the six months ended in Dec. 2023 was A$1.00 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

Neurizon Therapeutics's cash payments for the six months ended in Dec. 2023 was A$-1.06 Mil.

3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.

Neurizon Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.

Neurizon Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.

Neurizon Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

6. Interest Received:
It represents interest received by the company in the direct cash flow method.

Neurizon Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.

Neurizon Therapeutics's cash payments for the six months ended in Dec. 2023 was A$0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

Neurizon Therapeutics's cash flow from others for the six months ended in Dec. 2023 was A$0.00 Mil.

Neurizon Therapeutics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Neurizon Therapeutics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurizon Therapeutics Business Description